Argenx
Willemstraat 5
Breda
4811 AH
Tel: 31-0-10-763-030-488
Website: http://www.argenx.com/
Email: nfo@argenx.com
About Argenx
argenx a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe auto-immune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE AntibodyTM Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates.YEAR FOUNDED:
2008
LEADERSHIP:
CEO: Tim Van Hauwermeiren
CFO: Eric Castaldi
CSO: Hans de Haard
CDO: Torsten Dreier
CMO: Nicolas Leupin
JOBS:
Please click here for Argenx job opportunities.
CLINICAL TRIAL:
Please click here for clinical trial information.
134 articles with Argenx
-
argenx Reports First Quarter 2022 Financial Results and Provides Business Update
5/5/2022
argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, reported financial results for the first quarter 2022 and provided a business update.
-
argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia
5/5/2022
argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced positive data from the Phase 3 ADVANCE trial of VYVGART® in adults with primary ITP.
-
argenx to Present at BofA Securities 2022 Healthcare Conference
5/4/2022
argenx announced that members of management will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 at 10:40 a.m. P.T. in Las Vegas, NV.
-
argenx to Report First Quarter 2022 Financial Results and Business Update on May 5, 2022
4/28/2022
argenx announced that it will host a conference call and audio webcast on Thursday, May 5, 2022 at 2:30 pm CET to discuss its first quarter 2022 financial results and provide a business update.
-
Discover what's in store for today's presentations at The American Academy of Neurology’s annual meeting, which will include data for a variety of neurological treatments.
-
argenx Presents Interim Results from ADAPT+ Open-Label Extension Study Evaluating VYVGART® (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis at 2022 AAN Annual Meeting
4/5/2022
argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced interim results from ADAPT+, an ongoing Phase 3, open-label, three-year extension study evaluating long-term safety, tolerability and efficacy of VYVGART® for the treatment of adults with gMG.
-
argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting
4/1/2022
argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that interim data will be presented from ADAPT+ at the American Academy of Neurology Annual Meeting in Seattle, WA, April 2-7.
-
argenx announces full exercise of underwriters’ option to purchase additional ADSs
3/29/2022
argenx SE announced that the underwriters of its previously announced global offering of ordinary shares have exercised in full their option to purchase 350,000 additional ordinary shares in the form of ADSs on the same terms and conditions as the global offering.
-
Although it was relatively quiet in COVID-19-related clinical trials, there was plenty of other clinical trial news. Here’s a look.
-
argenx raises $700 million in gross proceeds in a global offering
3/24/2022
argenx SE announced the pricing of a global offering of ordinary shares represented by American Depository Shares in the United States and certain other countries outside of the European Economic Area and a simultaneous private placement of ordinary shares in the European Economic Area and the United Kingdom.
-
Data from the Phase III study showed that efgartigimod achieved the primary endpoint of total IgG reduction from the baseline on the 29th day of observation.
-
argenx Announces Positive Topline Phase 3 Data From ADAPT-SC Study Evaluating Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
3/22/2022
argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced positive topline data from the Phase 3 ADAPT-SC study evaluating subcutaneous efgartigimod for the treatment of generalized myasthenia gravis.
-
argenx announces launch of proposed global offering
3/22/2022
argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that it has commenced a global offering of $500 million of ordinary shares, which may be represented by American Depository Shares.
-
argenx Reports Full Year 2021 Financial Results and Provides Fourth Quarter Business Update
3/3/2022
argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, reported financial results for the full year 2021 and provided a fourth quarter business update.
-
IQVIA selected to accelerate clinical development of VYVGART™ (efgartigimod alfa fcab) by argenx SE
3/1/2022
IQVIA selected to accelerate clinical development of VYVGART™ (efgartigimod alfa fcab) by argenx SE.
-
argenx to Report Full Year 2021 Financial Results and Fourth Quarter Business Update on March 3, 2022
2/24/2022
argenx announced that it will host a conference call and audio webcast on Thursday, March 3, 2022 at 2:30 pm CET to discuss its full year 2021 financial results and provide a fourth quarter business update.
-
argenx to Present at the 11th Annual SVB Leerink Global Healthcare Conference
2/10/2022
argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that members of management will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 10:40 a.m. ET.
-
argenx Announces VYVGART™ Approval in Japan for the Treatment of Generalized Myasthenia Gravis
1/20/2022
argenx SE announced that Japan’s Ministry of Health, Labour and Welfare has approved VYVGART™ intravenous infusion for the treatment of adult patients with generalized myasthenia gravis who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies.
-
argenx Highlights Strategic Priorities for 2022
1/7/2022
argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced its strategic priorities for 2022 and highlighted recent achievements from its broad immunology pipeline.
-
VYVGART is the first-and-only neonatal Fc receptor (FcRn) blocker to be approved by the FDA.